Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification
Reexamination Certificate
2007-08-07
2007-08-07
Chen, Stacy B. (Department: 1648)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
C435S005000, C435S069100, C424S233100
Reexamination Certificate
active
10031313
ABSTRACT:
The invention relates to a structural protein of adeno-associated virus (AAV) that contains at least one modification that reduces the antigenicity of the virus. The invention further relates to the production of the structural protein and to its use.
REFERENCES:
patent: 5276136 (1994-01-01), Skubitz et al.
patent: 6491907 (2002-12-01), Rabinowitz et al.
patent: 2001/0031463 (2001-10-01), Kleinschmidt et al.
patent: 2002/0192823 (2002-12-01), Bartlett
patent: WO 95/23867 (1995-09-01), None
patent: WO 96/00587 (1996-01-01), None
patent: WO 97/08298 (1997-03-01), None
patent: WO 97/38723 (1997-10-01), None
patent: WO 97/38723 (1997-10-01), None
patent: WO 99/67393 (1999-12-01), None
Aumailley et al., “Identification of the Arg-Gly-Asp Sequence in Laminin A Chain as a Latent Cell-Binding Site Being Exposed in Fragment P1,”FEBS262:82-86 (1990).
Bartlett et al., “Targeted Adeno-Associated Virus Vector Transduction of Nonpermissive Cells Mediated by a Bispecific F (ab′Y)2Antibody,”Nature Biotechnology17:181-186 (1999).
Chapman et al., “Structure, Sequence, and Function Correlations Among Parvoviruses,”Virology194:491-508 (1993).
Chiorini et al., “High-Efficiency Transfer of the T Cell Co-Stimulatory Molecular B7-2 to Lymphoid Cells Using High-Titer Recombinant Adeno-Associated Virus Vectors,”Human Gene Therapy6:1531-1541 (1995).
Cosset et al., “Targeting Retrovirus Entry,”Gene Therapy3:946-956 (1996).
Douglas et al., “Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors,”Nature Biotechnology14:1574-1578 (1996).
Girod et al., “Genetic Capsid Modifications Allow Efficient Re-Targeting of Adeno-Associated Virus Type 2,”Nature Medicine5:1052-1056 (1999).
Hermonat et al., “Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants,”Journal of Virology51:329-339 (1984).
Luo et al., “Preliminary X-Ray Crystallographic Analysis of Canine Parovirus Crystals,”J. Mol. Biol.200:209-211 (1988).
Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector For Human Gene Therapy,”Human Gene Therapy5:793-801 (1994).
Krasnykh et al., “Generation of Recombinant Adenovirus Vectors With Modified Fibers for Altering Viral Tropism,”Journal of Virology70:6839-6846 (1996).
Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,”Current Topics in Microbiology and Immunology158:97-129 (1992).
Nimako et al., “Human Papillomavirus-Specific Cytotoxic T Lymphocytes in Patients with Cervical Intraepithelial Neoplasia Grade III,”Cancer Research57:4855-4861 (1997).
Ohno et al., “Cell-Specific Targeting of Sindbis Virus Vectors Displaying IgG-Binding Domains of Protein A,”Nature Biotechnology15:763-767 (1997).
Ruffing et al., “Mutations in the Carboxy Terminus of Adeno-Associated Virus 2 Capsid Proteins Affect Viral Infectivity: Lack of an RGD Integrin-Binding Motif,”Journal of General Virology75:3385-3392 (1994).
Ruffing et al., “Assembly of Viruslike Particles by Recombinant Structural Proteins of Adeno-Associated Virus Type 2 in Insect Cells,”Journal of Virology66:6922-6930 (1992).
Rutledge et al., “Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2,”Journal of Virology72:309-319 (1998).
Steinbach et al., “Assembly of Adeno-Associated Virus Type 2 Capsids in vitro,”Journal of General Virology78:1453-1462 (1997) (Abstract).
Stevenson et al., “Selective Targeting Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein,”Journal or Virology71:4782-4790 (1997).
Srivastava et al., “Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome,”Journal of Virology45:555-564 (1983).
Tarpey et al., “Human Cytotoxic T Lymphocytes Stimulated by Endogenously Processed Human Papillomavirus Type 11 E7 Recognize a Peptide Containing a HLA-A2 (A*0201) Motif,”Immunology81:222-227 (1994).
Tsao et al., “The Three-Dimensional Structure of Canine Parvovirus and Its Functional Implications,”Science251:1456-1464 (1991).
Valsesia-Wittmann et al., Modifications in the Binding Domain of Avian Retrovirus Envelope Protein to Redirect the Host Range of Retorviral VectorsJournal of Virology68:4609-4619 (1994).
Wickham et al., “Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins,”Journal of Virology71:8221-8229 (1997).
Wistuba et al., “Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly,”Journal of Virology71:1341-1352 (1997).
Wistuba et al., “Intermediates of Adeno-Associated Virus Type 2 Assembly: Identification of Soluble Complexes Containing Rep and Cap Proteins,”Journal of Virology69:5311-5319 (1995).
Wu et al., “The Canine Parvovirus Empty Capsid Structure,”J. Mol. Biol. 233:231-244 (1993).
Yang et al., “Development of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy,”Human Gene Therapy9:1929-1937 (1998).
Anderson, “Human Gene Therapy,”Nature392:25-30 (1998).
Asokan et al., “AAV Does the Shuffle,”Nature Biotechnology24:158-160 (2006).
Buning et al., “Receptor Targeting of Adeno-Associated Virus Vectors,”Gene Therapy10:1142-1151 (2003).
Grifman et al., “Incorporation fo Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids,”Molecular Therapy3:964-975 (2001).
Hoque et al., “Nuclear Transport of the Major Capsid Protein is Essential for Adeno-Associated Virus Capsid Formation,”Journal of Virology73:7912-7915 (1999).
Huttner et al., “Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce the Affinity and the Neutralizing Effects of Human Serum Antibodies,”Gene Therapy10:2139-2147 (2003).
Kmiec, “Gene Therapy,”American Scientist87:240-247 (1999).
Maass et al., “Recombinant Adeno-Associated Virus for the Generation of Autologous, Gene-Modified Tumor Vaccines: Evidence for a High Transduction Efficiency into Primary Epithelial Cancer Cells,”Human Gene Therapy9:1049-1059 (1998).
Maheshri et al., “Directed Evolution of Adeno-Associated Virus Yields Enhanced Gene Delivery Vectors,”Nature Biotechnology24:198-204 (2006).
Marshall, “Second Child in French Trial is Found to Have Leukemia,”Science299:320 (2003).
Meng et al., “Tumor Suppressor Genes as Targets for Cancer Gene Therapy,”Gene Therapy of Cancer Chapter1, pp. 3-18 (1999).
Mizukami et al., “Adeno-Associated Virus Type 2 Binds to a 150-Kilodalton Cell Membrane Glycoprotein,”Virology217:124-130 (1996).
Moskalenko et al., “Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure,”Journal of Virology74:1761-1766 (2000).
Nicklin et al., “Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells,”Molecular Therapy4:174-181 (2001).
Perabo et al., “In Vitro Selection of Viral Vectors with Modified Tropism: The Adeno-Associated Virus Display,”Molecular Therapy8:151-157 (2003).
Qing et al., “Human Fibroblast Growth Factor Receptor 1 is a Co-Receptor for Infection by Adeno-Associated Virus 2,”Nature Medicine5:71-77 (1999).
Ried et al., “Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors,”Journal of Virology76:4559-4566 (2002).
Russell, “Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects,”European Journal of Cancer30A:1165-1171 (1994).
Shi et al., “Insertional Mutagenesis of
Girod Anne
Hallek Michael
Ried Martin
Chen Stacy B.
Clark & Elbing LLP
MediGene AG
LandOfFree
Structural protein of adeno-associated virus with modified... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Structural protein of adeno-associated virus with modified..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Structural protein of adeno-associated virus with modified... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3878580